The demonstration of protein expression and biological efficacy of gene delivery systems is critical to the successful development of gene transfer vectors and therapies. A cell physiology and tissue culture core has been in operation at Johns Hopkins University since 1989 funded by the Cystic Fibrosis Foundation through the Research Development Program. This core has considerable expertise in the following areas: assaying for normal and defective function of CFTR by general assays such as: 1. 36Cl- efflux and SPQ and more specific assays such as patch clamping; 2. generating polyclonal anti-CFTR antibodies in both rabbit and chicken; 3. assaying for protein expression by Western blotting; and 4. determining the distribution of CFTR in heterologous cells and in animal (rabbit, rat and primate) cells. Work from this core was instrumental in the identification of adenoviral (12) and adeno-associated virus (2,3-6) systems as potential therapeutic agents which has caused much excitement lately and resulted in five protocols approved by the RAC (Recombinant DNA committee). The recent development of gene transfer technologies as potential therapies has increased the need of our Expression Core. The current Cell Physiology and Tissue Culture Core will be expanded to meet the needs of this new Gene Therapy Center. The Expression Core will be both a research and development core as well as providing support for the projects within this Gene Therapy Center.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL051811-05
Application #
6242303
Study Section
Project Start
1997-09-01
Project End
1999-08-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
5
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Kates, Max; Date, Abhijit; Yoshida, Takahiro et al. (2017) Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer. Clin Cancer Res 23:6592-6601
Guggino, William B; Benson, Janet; Seagrave, JeanClare et al. (2017) A Preclinical Study in Rhesus Macaques for Cystic Fibrosis to Assess Gene Transfer and Transduction by AAV1 and AAV5 with a Dual-Luciferase Reporter System. Hum Gene Ther Clin Dev 28:145-156
Schuster, Benjamin S; Allan, Daniel B; Kays, Joshua C et al. (2017) Photoactivatable fluorescent probes reveal heterogeneous nanoparticle permeation through biological gels at multiple scales. J Control Release 260:124-133
Schneider, Craig S; Xu, Qingguo; Boylan, Nicholas J et al. (2017) Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation. Sci Adv 3:e1601556
Duncan, Gregg A; Jung, James; Joseph, Andrea et al. (2016) Microstructural alterations of sputum in cystic fibrosis lung disease. JCI Insight 1:e88198
Yu, Tao; Chisholm, Jane; Choi, Woo Jin et al. (2016) Mucus-Penetrating Nanosuspensions for Enhanced Delivery of Poorly Soluble Drugs to Mucosal Surfaces. Adv Healthc Mater 5:2745-2750
Schuster, Benjamin S; Ensign, Laura M; Allan, Daniel B et al. (2015) Particle tracking in drug and gene delivery research: State-of-the-art applications and methods. Adv Drug Deliv Rev 91:70-91
Mastorakos, Panagiotis; da Silva, Adriana L; Chisholm, Jane et al. (2015) Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy. Proc Natl Acad Sci U S A 112:8720-5
Suk, Jung Soo; Kim, Anthony J; Trehan, Kanika et al. (2014) Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier. J Control Release 178:8-17
Smith, Laura J; Ul-Hasan, Taihra; Carvaines, Sarah K et al. (2014) Gene transfer properties and structural modeling of human stem cell-derived AAV. Mol Ther 22:1625-34

Showing the most recent 10 out of 123 publications